Found 491 with Last Name = 'taddei' and Initial = 'dm' 
Affinity DataIC50: 1nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα
isoform (MAPK14: Invitrogen), are evaluated indirectly by determining
the l...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα
isoform (MAPK14: Invitrogen), are evaluated indirectly by determining
the l...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα
isoform (MAPK14: Invitrogen), are evaluated indirectly by determining
the l...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: <2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Respivert
US Patent
Respivert
US Patent
Affinity DataIC50: 2.5nMAssay Description:The PI3K enzymes catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
